Fri, February 9, 2018

David Lebovitz Maintained (ALNY) at Hold with Decreased Target to $118 on, Feb 9th, 2018

David Lebovitz of Morgan Stanley, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Hold with Decreased Target from $128 to $118 on, Feb 9th, 2018.

David has made no other calls on ALNY in the last 4 months.



There are 6 other peers that have a rating on ALNY. Out of the 6 peers that are also analyzing ALNY, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Paul Matteis of "Leerink Swann" Maintained at Hold with Increased Target to $135 on, Thursday, January 25th, 2018


These are the ratings of the 5 analyists that currently disagree with David


  • Anupam Rama of "JP Morgan" Upgraded from Hold to Buy on, Thursday, November 9th, 2017
  • Geoff Meacham of "Barclays" Maintained at Buy with Increased Target to $158 on, Wednesday, November 8th, 2017
  • Madhu Kumar of "B. Riley Securities" Maintained at Strong Buy with Decreased Target to $220 on, Wednesday, November 8th, 2017
  • Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $151 on, Friday, November 3rd, 2017
  • Rahul Jasuja of "FBR Capital" Maintained at Strong Buy with Increased Target to $240 on, Thursday, November 2nd, 2017